| Literature DB >> 35156896 |
Tao Zhang1, Zhengjie Zhu1, Hongtao Yang1, Shili Cao1, Jing Li2, Qingmiao Shao3.
Abstract
BACKGROUND: Red blood cell distribution width (RDW) has emerged as a prognostic marker of atrial fibrillation (AF) in various clinical settings. However, the relationship by which RDW was linked to AF in hemodialysis (HD) patients was not clear. We sought to reveal the relationship between RDW and AF occurrence in HD patients.Entities:
Keywords: Red blood cell distribution width; hemodialysis; non-valvular atrial fibrillation
Mesh:
Year: 2022 PMID: 35156896 PMCID: PMC8856061 DOI: 10.1080/0886022X.2021.2019588
Source DB: PubMed Journal: Ren Fail ISSN: 0886-022X Impact factor: 2.606
Figure 1.The flowchart of the selected population in this study.
Baseline clinical and echocardiographic characteristics of study population.
| Non-AF ( | AF ( | ||
|---|---|---|---|
| Age, years | 49.71 ± 1.79 | 61.0 ± 1.48 | <0.001 |
| Sex, female ( | 34 (40.5) | 42 (48.8) | 0.285 |
| Diabetes mellitus ( | 40 (47.6) | 50 (58.6) | 0.219 |
| Hypertension ( | 84 (100) | 86 (100) | |
| BMI (kg/m2) | 25.8 ± 3.87 | 24.3 ± 4.11 | 0.015 |
| Stroke ( | 20 (23.8) | 28 (32.6) | 0.235 |
| Smoking habit ( | 28 (33.3) | 24 (27.9) | 0.507 |
| Drinking habit ( | 17 (23.8) | 16 (18.6) | 0.456 |
| Number of dialysis (week) | 3.00 ± 0.00 | 3.02 ± 0.150 | 0.162 |
| Time of dialysis (mon) | 27.81 ± 5.02 | 25.26 ± 3.70 | 0.681 |
| Single pool-Kt/V | 1.28 ± 0.15 | 1.27 ± 0.20 | 0.829 |
| CHA2DS2-VASc score | 3.42 ± 1.20 | ||
| LADS score | 1.50 ± 0.83 | 1.65 ± 0.76 | 0.218 |
| HATCH score | 1.73 ± 0.96 | 2.01 ± 0.90 | 0.003 |
| Previous medication ( | |||
| ACEI/ARB | 36 (42.9) | 36 (41.9) | 1.000 |
| Beta-blocker | 52 (61.9) | 60 (69.8) | 0.332 |
| Calcium channel blocker | 76 (90.5) | 72 (83.7) | 0.254 |
| Aspirin | 17 (20.2) | 18 (20.9) | 1.000 |
| Statin | 12 (14.3) | 20 (23.3) | 0.170 |
| Calcium | 29 (34.5) | 26 (30.2) | 0.624 |
| Dephosphorization agent | 37 (44.0) | 34 (39.5) | 0.641 |
| Iron | 30 (35.7) | 28 (32.6) | 0.747 |
| Erythropoietin | 84 (100) | 84 (97.7) | 0.497 |
| VKA or Rivaroxaban | 3 (3.6) | 12 (14.0) | 0.028 |
| Echocardiographic indicator | |||
| LAD (mm) | 37.68 ± 5.08 | 39.87 ± 3.66 | 0.001 |
| IVST (mm) | 10.32 ± 1.43 | 10.54 ± 1.44 | 0.307 |
| LVPWT (mm) | 9.36 ± 1.26 | 9.59 ± 2.13 | 0.387 |
| LVEDD (mm) | 50.33 ± 6.96 | 50.07 ± 5.92 | 0.790 |
| LVEF (%) | 60.81 ± 9.72 | 58.44 ± 10.53 | 0.130 |
BMI: body mass index; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocking agents; LAD: left atrial diameter; IVST: interventricular septal thickness; LVPWT: left ventricular posterior wall thickness: LVEDD: left ventricular end-diastolic diameter; LVEF: Left ventricular ejection fraction.
Laboratory parameters of study population.
| Non-AF ( | AF ( | ||
|---|---|---|---|
| White blood cell Count (10*9/L) | 6.62 ± 1.68 | 6.36 ± 1.74 | 0.319 |
| Red blood cell Count (10*12/L) | 3.71 ± 0.67 | 3.53 ± 0.68 | 0.081 |
| Hemoglobin (g/L) | 108.14 ± 19.14 | 102.63 ± 18.49 | 0.058 |
| Red blood cell distribution width (%) | 14.26 ± 0.82 | 15.10 ± 0.96 | <0.001 |
| Serum creatinine (µmol/L) | 691.93 ± 30.8 | 693.45 ± 20.47 | 0.967 |
| Urea nitrogen (mmol/L) | 20.26 ± 9.75 | 20.96 ± 7.48 | 0.600 |
| Uric acid (µmol/L) | 371.79 ± 14.4 | 384.40 ± 8.41 | 0.448 |
| Serum potassium (mmol/L) | 4.70 ± 0.62 | 4.51 ± 0.71 | 0.059 |
| Carbon dioxide binding capacity (mmol/L) | 21.15 ± 0.43 | 21.37 ± 0.34 | 0.674 |
| Fasting blood-glucose (mmol/L) | 6.67 ± 0.83 | 6.78 ± 0.79 | 0.381 |
| C-reactive protein (mg/L) | 20.99 ± 1.56 | 20.31 ± 1.63 | 0.764 |
| Triglyceride (mmol/L) | 1.77 ± 0.14 | 2.08 ± 0.21 | 0.224 |
| Total cholesterol (mmol/L) | 4.36 ± 1.63 | 4.66 ± 1.30 | 0.193 |
| Low density lipoprotein cholesterol (mmol/L) | 2.34 ± 0.14 | 2.64 ± 0.11 | 0.187 |
| Serum calcium(mmol/L) | 2.19 ± 0.17 | 2.18 ± 0.23 | 0.665 |
| Serum phosphorus(mmol/L) | 1.83 ± 0.67 | 1.69 ± 0.47 | 0.099 |
| Total parathyroid hormone (pg/mL) | 398.10 ± 23.76 | 405.30 ± 42.61 | 0.884 |
| Serum magnesium (mmol/L) | 1.04 ± 0.14 | 0.97 ± 0.25 | 0.052 |
| Plasma albumin (g/L) | 36.10 ± 0.94 | 35.52 ± 0.56 | 0.591 |
| Aspartate aminotransferase (U/L) | 13.40 ± 0.46 | 12.73 ± 0.67 | 0.408 |
| Alanine aminotransferase (U/L) | 13.81 ± 0.72 | 11.46 ± 1.27 | 0.110 |
| Homocysteine cycle enzyme (µmol/L) | 30.88 ± 2.55 | 30.70 ± 2.27 | 0.957 |
| Serum iron concentration (µmol/L) | 10.09 ± 0.65 | 10.86 ± 0.66 | 0.405 |
| Total iron binding force (µmol/L) | 45.28 ± 9.12 | 44.50 ± 10.18 | 0.600 |
| Iron transferrin saturation (%) | 24.19 ± 1.86 | 25.47 ± 1.69 | 0.613 |
Multivariate logistic regression analysis on predictors of paroxysmal AF in the HD population.
| B | SE | Wald | OR | 95% CI | |||
|---|---|---|---|---|---|---|---|
| Age, per 1 year increase | 0.030 | 0.013 | 5.074 | 0.024 | 1.030 | 1.004 | −1.057 |
| BMI, per 1kg/m2increase | −0.148 | 0.050 | 8.637 | 0.003 | 0.863 | 0.782 | −0.952 |
| RDW, per 1% increase | 1.071 | 0.245 | 19.091 | <0.001 | 2.917 | 1.805 | −4.715 |
| LAD, per 1mm increase | 0.093 | 0.045 | 4.160 | 0.041 | 1.097 | 1.004 | −1.199 |
| HATCH score, per 1 score increase | 0.295 | 0.227 | 1.683 | 0.195 | 1.343 | 0.860 | −2.095 |
BMI: body mass index; RDW: red blood cell distribution width; LAD: left atrial diameter; HATCH score represented hypertension, age, ischemic events, chronic obstructive pulmonary disease, and heart failure.
Figure 2.Receiver-operating characteristic (ROC) curves for RDW and LAD values in prediction of AF in HD patients.